Suprefort with and without Cerluten and Endoluten in type 2 diabetes
Comparison in people · 2013
- What was studied
- 918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.
- Main finding
- The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.
Glucose two hours after challenge · 9.7 ± 0.5 mmol/L with standard care, 7.3 ± 0.6 with added Suprefort, 6.5 ± 0.4 with the three-product combination. · Both adjunctive arms are marked significant versus standard care. Exact p values are unavailable.
Reported findings and study design
Moscow, February 2011 to April 2012. Standard treatment alone (329), plus Suprefort (214), or plus Suprefort, Cerluten and Endoluten (375). Suprefort and Cerluten were given orally as two capsules each per day for three months. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified in this source.
Population or model 918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Glucose two hours after challenge | 9.7 ± 0.5 mmol/L with standard care, 7.3 ± 0.6 with added Suprefort, 6.5 ± 0.4 with the three-product combination. | Both adjunctive arms are marked significant versus standard care. Exact p values are unavailable. |
| Fasting glucose | 6.8 ± 0.6, 6.1 ± 0.5 and 5.6 ± 0.4 mmol/L, respectively. | Both adjunctive arms are marked significant versus standard care. |
| Standard medication dose reportedly reduced | 0/329 standard care, 114/214 (53.3%) added Suprefort, 279/375 (74.4%) three-product combination. | Medication-adjustment criteria and timing are unspecified. |
| Glucose response counts | Suprefort arm: 195/214 (91.1%) reached the reported upper normal limit by day 18. Three-product arm: 348/375 (92.8%) reportedly normalized by day 12. | These outcomes use different assessment days and wording. |
Blood glucose in the three reported groups
| Treatment group | Participants | Fasting before | Fasting after | Two-hour before | Two-hour after |
|---|---|---|---|---|---|
| Standard care | 329 | 8.4 ± 0.6 | 6.8 ± 0.6 | 13.8 ± 0.4 | 9.7 ± 0.5 |
| Standard care + Suprefort | 214 | 8.2 ± 0.7 | 6.1 ± 0.5 | 13.4 ± 0.6 | 7.3 ± 0.6 |
| Standard care + Suprefort, Cerluten and Endoluten | 375 | 8.3 ± 0.7 | 5.6 ± 0.4 | 13.6 ± 0.6 | 6.5 ± 0.4 |
Glucose in mmol/L. Table 3 leaves the timing and the meaning of the ± term unspecified.
The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. The reports do not give a systematic harms assessment. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- Allocation, masking, treatment adjustments, exact timing of Table 3 and analysis denominators are unspecified. The response counts use different assessment days.
- The 918-person Moscow comparison has a different site and design from the 59-person St. Petersburg Medical Center report. Participant-level linkage is unavailable.
- The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
Source details
Conference report · company reproduction
Authors’ conference material, Russian reproduction, PDF pages 11–13, methods and Table 3. English and Russian editions describe the same cohort.
Sources checked
Citation
D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov. Suprefort with and without Cerluten and Endoluten in type 2 diabetes 20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides.
Related compounds
Suprefort
A peptide mixture extracted from animal pancreas, studied in institute reports on pancreatitis and digestive enzymes.
Cerluten
An animal brain-derived peptide mixture investigated in institute reports and used in the Gazprom occupational research program.
Endoluten
An animal pineal-gland peptide mixture used in the Gazprom occupational research program.